Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen Inc. Announces Positive Top-Line Results From Otezla? Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis

12/01/2021 | 04:00pm EST

Amgen Inc. announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla? (apremilast) in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a clinically meaningful and statistically significant improvement, compared with placebo, in the primary endpoint of the modified static Physician's Global Assessment of Genitalia (sPGA-G) response (defined as an sPGA-G score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline) at week 16. In addition, all secondary endpoints were also met with meaningful and significant improvements in Genital Psoriasis Itch Numerical Rating Scale (GPI-NRS) response (defined as at least a 4-point reduction from baseline in GPI-NRS item score within the Genital Psoriasis Symptoms for subjects with a baseline score of = 4); affected body surface area (BSA) change from baseline; Dermatology Life Quality Index (DLQI) change from baseline; and static Physician's Global Assessment (sPGA) response (defined as sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline) at week 16 with Otezla versus placebo. The type and rate of adverse events observed in this trial were consistent with the known safety profile of Otezla. The most commonly reported adverse events that occurred in at least 5% of patients in either treatment group were diarrhea, headache, nausea and nasopharyngitis. Patients completing the double-blind phase of the trial continued or switched to Otezla during the extension phase of the study and will be treated through week 32. The study is ongoing and is planned to complete in the first half of 2022. Detailed results from the 16-week double-blind phase of the study will be submitted for presentation at an upcoming medical conference.


ę S&P Capital IQ 2021
All news about AMGEN INC.
01/14AMGEN : Teneobio Acquisition Adds Talent and New Types of Antibodies to Amgen
PU
01/13BridgeBio to Study BBP-398 With Amgen's Lumakras in Solid Tumors
DJ
01/13BridgeBio Pharma, Amgen Team Up to Evaluate Combination Treatment for Advanced Solid Tu..
MT
01/13Amgen, AstraZeneca's Asthma Drug Tezspire Available For Shipment to US Wholesalers
MT
01/13BridgeBio Pharma, Inc. Announces Clinical Collaboration with Amgen Inc. to Study BBP-39..
CI
01/13TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT..
PR
01/13Amgen and Astrazeneca Announces Tezspire™ Is Available for Shipment to Wholesalers..
CI
01/12AMGEN : Going Beyond Skin Deep When Managing Plaque Psoriasis
PU
01/11Amgen - EUROPEAN COMMISSION APPROVES LUMYKRAS (SOTORASIB) FOR PATIENTS WITH KRAS G12C-M..
AQ
01/11Amgen, Arrakis Start Research Project For RNA Degrader Treatments For Several Diseases;..
MT
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 019 M - -
Net income 2021 5 559 M - -
Net Debt 2021 21 986 M - -
P/E ratio 2021 23,2x
Yield 2021 2,96%
Capitalization 133 B 133 B -
EV / Sales 2021 5,94x
EV / Sales 2022 5,61x
Nbr of Employees 24 300
Free-Float -
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 235,36 $
Average target price 238,36 $
Spread / Average Target 1,28%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.4.62%132 570
JOHNSON & JOHNSON-1.35%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317